ATE370951T1 - Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen - Google Patents

Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE370951T1
ATE370951T1 AT00929625T AT00929625T ATE370951T1 AT E370951 T1 ATE370951 T1 AT E370951T1 AT 00929625 T AT00929625 T AT 00929625T AT 00929625 T AT00929625 T AT 00929625T AT E370951 T1 ATE370951 T1 AT E370951T1
Authority
AT
Austria
Prior art keywords
production
pharmaceutical compositions
compositions containing
purine derivatives
purine
Prior art date
Application number
AT00929625T
Other languages
English (en)
Inventor
Jean-Luc Haesslein
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE370951T1 publication Critical patent/ATE370951T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00929625T 1999-05-21 2000-05-18 Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen ATE370951T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Publications (1)

Publication Number Publication Date
ATE370951T1 true ATE370951T1 (de) 2007-09-15

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929625T ATE370951T1 (de) 1999-05-21 2000-05-18 Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Country Status (33)

Country Link
US (2) US7122669B1 (de)
EP (1) EP1183256B1 (de)
JP (1) JP2003500407A (de)
KR (1) KR100707895B1 (de)
CN (1) CN1298719C (de)
AP (1) AP1477A (de)
AR (1) AR035317A1 (de)
AT (1) ATE370951T1 (de)
AU (1) AU4764500A (de)
BR (1) BR0011282A (de)
CA (1) CA2374714A1 (de)
CZ (1) CZ20014163A3 (de)
DE (1) DE60036102T2 (de)
DK (1) DK1183256T3 (de)
DZ (1) DZ3166A1 (de)
EA (1) EA005072B1 (de)
ES (1) ES2290033T3 (de)
FR (1) FR2793794B1 (de)
HU (1) HUP0201649A3 (de)
IL (1) IL146441A0 (de)
MA (1) MA26791A1 (de)
MX (1) MXPA01011834A (de)
NO (1) NO20015659L (de)
NZ (1) NZ515556A (de)
PL (1) PL352293A1 (de)
PT (1) PT1183256E (de)
SK (1) SK16722001A3 (de)
TR (1) TR200103349T2 (de)
TW (1) TWI284130B (de)
UA (1) UA68441C2 (de)
WO (1) WO2000071543A1 (de)
YU (1) YU86601A (de)
ZA (1) ZA200109602B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
EP1377579B1 (de) * 2000-10-31 2009-03-25 Aventis Pharmaceuticals Inc. Acyl- und sulfonylderivative 6,9-disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
EP1578722A4 (de) * 2001-10-12 2006-09-06 Irm Llc Kinaseinhibitorgerüste und verfahren zu deren herstellung
US7273864B2 (en) 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7592177B2 (en) 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
EP1740587A4 (de) * 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Selektive antagonisten von a2a-adenosinrezeptoren
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP4086257A1 (de) * 2016-09-30 2022-11-09 SRI International Duale clk/cdk1-inhibitoren zur krebsbehandlung
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
KR20250121114A (ko) 2022-12-16 2025-08-11 아스트라제네카 아베 2,6,9-삼치환된 퓨린

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0545412A3 (en) * 1991-12-05 1993-11-03 Texas Instruments Inc Method and apparatus to improve a video signal
AU658698B2 (en) * 1991-12-06 1995-04-27 Aventis Pharmaceuticals Inc. Novel trans cyclopentanyl purine analogs useful as immunosuppressants
PT874846E (pt) * 1995-11-01 2003-08-29 Novartis Ag Derivados de purina e processos para a sua preparacao
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
US20050187228A1 (en) 2005-08-25
MA26791A1 (fr) 2004-12-20
EA200101224A1 (ru) 2002-10-31
AR035317A1 (es) 2004-05-12
CZ20014163A3 (cs) 2002-10-16
PT1183256E (pt) 2007-11-13
TWI284130B (en) 2007-07-21
PL352293A1 (en) 2003-08-11
ZA200109602B (en) 2003-01-29
AP1477A (en) 2005-10-19
BR0011282A (pt) 2002-02-26
DZ3166A1 (fr) 2000-11-30
DK1183256T3 (da) 2007-12-03
WO2000071543A1 (fr) 2000-11-30
NZ515556A (en) 2003-08-29
SK16722001A3 (sk) 2003-01-09
AP2001002355A0 (en) 2001-12-31
TR200103349T2 (tr) 2002-05-21
JP2003500407A (ja) 2003-01-07
UA68441C2 (en) 2004-08-16
AU4764500A (en) 2000-12-12
NO20015659D0 (no) 2001-11-20
EP1183256B1 (de) 2007-08-22
DE60036102D1 (de) 2007-10-04
EP1183256A1 (de) 2002-03-06
IL146441A0 (en) 2002-07-25
CN1361780A (zh) 2002-07-31
ES2290033T3 (es) 2008-02-16
HUP0201649A2 (en) 2002-08-28
CN1298719C (zh) 2007-02-07
YU86601A (sh) 2005-07-19
FR2793794A1 (fr) 2000-11-24
KR20010113975A (ko) 2001-12-28
EA005072B1 (ru) 2004-10-28
DE60036102T2 (de) 2008-05-15
US7122669B1 (en) 2006-10-17
HUP0201649A3 (en) 2003-01-28
FR2793794B1 (fr) 2001-07-27
CA2374714A1 (fr) 2000-11-30
US7208598B2 (en) 2007-04-24
KR100707895B1 (ko) 2007-04-17
NO20015659L (no) 2002-01-18
MXPA01011834A (es) 2002-04-17

Similar Documents

Publication Publication Date Title
ATE370946T1 (de) 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
ATE222251T1 (de) Substituierte heterocyclische verbindungen, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATA256092A (de) Aminosäurederivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE60036102D1 (de) Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE344034T1 (de) N-adamantylmethyl-derivate und zwischenprodukte als pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
ATE241613T1 (de) Pyrimidinderivate und verfahren zu deren herstellung
ATE323092T1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE337317T1 (de) Imidazopyrin-derivate, verfahren zu ihrer herstellung and sie enthaltende pharmazeutische zusamensetzungen
DE60022890D1 (de) Naphthyridine derivate, verfahren zu ihrer herstellung, deren anwendung und sie enthaltende pharmazeutische zusammensetzungen
DE60013463D1 (de) Pharmazeutische produkte und verfahren zu deren herstellung
DE69934781D1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
ATE194616T1 (de) Substituierte 4-phenyl-thiazole derivate, verfahren zu deren herstellung und pharmazeutische zusammenstellungen die sie enthalten
DE60033519D1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
ATA260590A (de) Glyzerinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung
ATE370942T1 (de) (1-phenacyl-3-phenyl-3- piperidylethyl)piperidinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE275136T1 (de) Morpholinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69423424D1 (de) Esculetinderivate, Verfahren zu deren Herstellung und deren Verwendung als pharmazeutische Zusammensetzungen
ATE244246T1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE248171T1 (de) Isoindoloindolon-derivate, verfahren zu ihrer herstellung und die enthaltende pharmazeutische zusammensetzungen
DE60007168D1 (de) Benzopyranyl-guanidin-derivate, verfahren zu deren herstellung sowie diese enthaltenden pharmazeutische zusammensetzungen
ATE292114T1 (de) Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen
ATE295358T1 (de) N-benzylpiperazin n-benzylpiperazine, verbindungen, verfahren zu deren herstellung und deren pharmazeutischen zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties